Johnson & Johnson Price to Sales Ratio 2010-2024 | JNJ
Historical PS ratio values for Johnson & Johnson (JNJ) over the last 10 years. The current P/S ratio for Johnson & Johnson as of April 26, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Johnson & Johnson P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-04-26 |
146.14 |
|
4.54 |
| 2024-03-31 |
158.19 |
$32.18 |
4.92 |
| 2023-12-31 |
155.56 |
$32.88 |
4.73 |
| 2023-09-30 |
153.36 |
$32.31 |
4.75 |
| 2023-06-30 |
161.82 |
$31.44 |
5.15 |
| 2023-03-31 |
150.39 |
$30.72 |
4.89 |
| 2022-12-31 |
170.20 |
$30.01 |
5.67 |
| 2022-09-30 |
156.39 |
$28.96 |
5.40 |
| 2022-06-30 |
168.80 |
$30.17 |
5.60 |
| 2022-03-31 |
167.48 |
$29.89 |
5.60 |
| 2021-12-31 |
160.62 |
$29.46 |
5.45 |
| 2021-09-30 |
150.63 |
$34.22 |
4.40 |
| 2021-06-30 |
152.74 |
$33.39 |
4.57 |
| 2021-03-31 |
151.44 |
$31.54 |
4.80 |
| 2020-12-31 |
144.12 |
$30.94 |
4.66 |
| 2020-09-30 |
135.38 |
$30.25 |
4.48 |
| 2020-06-30 |
127.04 |
$30.12 |
4.22 |
| 2020-03-31 |
117.63 |
$30.88 |
3.81 |
| 2019-12-31 |
130.01 |
$30.55 |
4.26 |
| 2019-09-30 |
114.52 |
$30.30 |
3.78 |
| 2019-06-30 |
123.28 |
$29.99 |
4.11 |
| 2019-03-31 |
122.89 |
$30.01 |
4.10 |
| 2018-12-31 |
112.71 |
$29.91 |
3.77 |
| 2018-09-30 |
119.91 |
$29.79 |
4.02 |
| 2018-06-30 |
104.60 |
$29.51 |
3.54 |
| 2018-03-31 |
109.66 |
$28.73 |
3.82 |
| 2017-12-31 |
118.81 |
$27.86 |
4.27 |
| 2017-09-30 |
109.88 |
$26.99 |
4.07 |
| 2017-06-30 |
111.10 |
$26.21 |
4.24 |
| 2017-03-31 |
103.92 |
$25.95 |
4.00 |
| 2016-12-31 |
95.50 |
$25.74 |
3.71 |
| 2016-09-30 |
97.25 |
$25.58 |
3.80 |
| 2016-06-30 |
99.20 |
$25.27 |
3.92 |
| 2016-03-31 |
87.86 |
$24.98 |
3.52 |
| 2015-12-31 |
82.81 |
$24.90 |
3.33 |
| 2015-09-30 |
74.71 |
$24.94 |
3.00 |
| 2015-06-30 |
77.39 |
$25.29 |
3.06 |
| 2015-03-31 |
79.31 |
$25.75 |
3.08 |
| 2014-12-31 |
81.86 |
$25.91 |
3.16 |
| 2014-09-30 |
82.91 |
$25.91 |
3.20 |
| 2014-06-30 |
80.83 |
$25.56 |
3.16 |
| 2014-03-31 |
75.37 |
$24.96 |
3.02 |
| 2013-12-31 |
69.77 |
$24.78 |
2.82 |
| 2013-09-30 |
65.58 |
$24.65 |
2.66 |
| 2013-06-30 |
64.47 |
$24.60 |
2.62 |
| 2013-03-31 |
60.76 |
$24.30 |
2.50 |
| 2012-12-31 |
51.83 |
$24.00 |
2.16 |
| 2012-09-30 |
50.51 |
$23.61 |
2.14 |
| 2012-06-30 |
49.07 |
$23.32 |
2.10 |
| 2012-03-31 |
47.45 |
$23.40 |
2.03 |
| 2011-12-31 |
46.77 |
$23.42 |
2.00 |
| 2011-09-30 |
45.00 |
$23.17 |
1.94 |
| 2011-06-30 |
46.59 |
$22.79 |
2.04 |
| 2011-03-31 |
41.14 |
$22.30 |
1.84 |
| 2010-12-31 |
42.56 |
$22.06 |
1.93 |
| 2010-09-30 |
42.27 |
$22.38 |
1.89 |
| 2010-06-30 |
39.91 |
$22.40 |
1.78 |
| 2010-03-31 |
43.66 |
$22.40 |
1.95 |
| 2009-12-31 |
42.81 |
$22.20 |
1.93 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$352.166B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
